Interplay between transcription regulators RUNX1 and FUBP1 activates an enhancer of the oncogene c-KIT and amplifies cell proliferation
Lydie Debaize, Hélène Jakobczyk, Stéphane Avner, Jérémie Gaudichon, Anne-Gaëlle Rio, Aurélien A Sérandour, Lena Dorsheimer, Frédéric Chalmel, Jason S Carroll, Martin Zörnig, Michael A Rieger, Olivier Delalande, Gilles Salbert, Marie-Dominique Galibert, Virginie Gandemer, Marie-Bérengère Troadec, Lydie Debaize, Hélène Jakobczyk, Stéphane Avner, Jérémie Gaudichon, Anne-Gaëlle Rio, Aurélien A Sérandour, Lena Dorsheimer, Frédéric Chalmel, Jason S Carroll, Martin Zörnig, Michael A Rieger, Olivier Delalande, Gilles Salbert, Marie-Dominique Galibert, Virginie Gandemer, Marie-Bérengère Troadec
Abstract
Runt-related transcription factor 1 (RUNX1) is a well-known master regulator of hematopoietic lineages but its mechanisms of action are still not fully understood. Here, we found that RUNX1 localizes on active chromatin together with Far Upstream Binding Protein 1 (FUBP1) in human B-cell precursor lymphoblasts, and that both factors interact in the same transcriptional regulatory complex. RUNX1 and FUBP1 chromatin localization identified c-KIT as a common target gene. We characterized two regulatory regions, at +700 bp and +30 kb within the first intron of c-KIT, bound by both RUNX1 and FUBP1, and that present active histone marks. Based on these regions, we proposed a novel FUBP1 FUSE-like DNA-binding sequence on the +30 kb enhancer. We demonstrated that FUBP1 and RUNX1 cooperate for the regulation of the expression of the oncogene c-KIT. Notably, upregulation of c-KIT expression by FUBP1 and RUNX1 promotes cell proliferation and renders cells more resistant to the c-KIT inhibitor imatinib mesylate, a common therapeutic drug. These results reveal a new mechanism of action of RUNX1 that implicates FUBP1, as a facilitator, to trigger transcriptional regulation of c-KIT and to regulate cell proliferation. Deregulation of this regulatory mechanism may explain some oncogenic function of RUNX1 and FUBP1.
Figures
References
- Sood R., Kamikubo Y., Liu P.. Role of RUNX1 in hematological malignancies. Blood. 2017; 129:2070–2082.
- Yzaguirre A.D., de Bruijn M.F.T.R., Speck N.A.. The role of Runx1 in embryonic blood cell formation. Adv. Exp. Med. Biol. 2017; 962:47–64.
- Brady G., Elgueta Karstegl C., Farrell P.J.. Novel function of the unique N-terminal region of RUNX1c in B cell growth regulation. Nucleic Acids Res. 2013; 41:1555–1568.
- Hayashi K., Natsume W., Watanabe T., Abe N., Iwai N., Okada H., Ito Y., Asano M., Iwakura Y., Habu S. et al. . Diminution of the AML1 transcription factor function causes differential effects on the fates of CD4 and CD8 single-positive T cells. J. Immunol. 2000; 165:6816–6824.
- Huang G., Zhang P., Hirai H., Elf S., Yan X., Chen Z., Koschmieder S., Okuno Y., Dayaram T., Growney J.D. et al. . PU.1 is a major downstream target of AML1 (RUNX1) in adult mouse hematopoiesis. Nat. Genet. 2008; 40:51–60.
- Ichikawa M., Asai T., Chiba S., Kurokawa M., Ogawa S.. Runx1/AML-1 ranks as a master regulator of adult hematopoiesis. Cell Cycle. 2004; 3:722–724.
- Ichikawa M., Yoshimi A., Nakagawa M., Nishimoto N., Watanabe-Okochi N., Kurokawa M.. A role for RUNX1 in hematopoiesis and myeloid leukemia. Int. J. Hematol. 2013; 97:726–734.
- Lorsbach R.B., Moore J., Ang S.O., Sun W., Lenny N., Downing J.R.. Role of RUNX1 in adult hematopoiesis: analysis of RUNX1-IRES-GFP knock-in mice reveals differential lineage expression. Blood. 2004; 103:2522–2529.
- Okuda T., van Deursen J., Hiebert S.W., Grosveld G., Downing J.R.. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell. 1996; 84:321–330.
- Wang Q., Stacy T., Binder M., Marin-Padilla M., Sharpe A.H., Speck N.A.. Disruption of the Cbfa2 gene causes necrosis and hemorrhaging in the central nervous system and blocks definitive hematopoiesis. Proc. Natl. Acad. Sci. U.S.A. 1996; 93:3444–3449.
- Bonifer C., Levantini E., Kouskoff V., Lacaud G.. Runx1 structure and function in blood cell development. Adv. Exp. Med. Biol. 2017; 962:65–81.
- Ito Y., Bae S.-C., Chuang L.S.H.. The RUNX family: developmental regulators in cancer. Nat. Rev. Cancer. 2015; 15:81–95.
- Huang G., Shigesada K., Ito K., Wee H.-J., Yokomizo T., Ito Y.. Dimerization with PEBP2β protects RUNX1/AML1 from ubiquitin–proteasome-mediated degradation. EMBO J. 2001; 20:723–733.
- Wang Q., Stacy T., Miller J.D., Lewis A.F., Gu T.L., Huang X., Bushweller J.H., Bories J.C., Alt F.W., Ryan G. et al. . The CBFbeta subunit is essential for CBFalpha2 (AML1) function in vivo. Cell. 1996; 87:697–708.
- Draper J.E., Sroczynska P., Tsoulaki O., Leong H.S., Fadlullah M.Z.H., Miller C., Kouskoff V., Lacaud G.. RUNX1B Expression is highly heterogeneous and distinguishes megakaryocytic and erythroid lineage fate in adult mouse hematopoiesis. PLoS Genet. 2016; 12:e1005814.
- Niebuhr B., Kriebitzsch N., Fischer M., Behrens K., Gunther T., Alawi M., Bergholz U., Muller U., Roscher S., Ziegler M. et al. . Runx1 is essential at two stages of early murine B-cell development. Blood. 2013; 122:413–423.
- Davis-Smyth T., Duncan R.C., Zheng T., Michelotti G., Levens D.. The far upstream element-binding proteins comprise an ancient family of single-strand DNA-binding transactivators. J. Biol. Chem. 1996; 271:31679–31687.
- Duncan R., Bazar L., Michelotti G., Tomonaga T., Krutzsch H., Avigan M., Levens D.. A sequence-specific, single-strand binding protein activates the far upstream element of c-myc and defines a new DNA-binding motif. Genes Dev. 1994; 8:465–480.
- Zhang J., Chen Q.M.. Far upstream element binding protein 1: a commander of transcription, translation and beyond. Oncogene. 2013; 32:2907–2916.
- Avigan M.I., Strober B., Levens D.. A far upstream element stimulates c-myc expression in undifferentiated leukemia cells. J. Biol. Chem. 1990; 265:18538–18545.
- Malz M., Weber A., Singer S., Riehmer V., Bissinger M., Riener M.-O., Longerich T., Soll C., Vogel A., Angel P. et al. . Overexpression of far upstream element binding proteins: A mechanism regulating proliferation and migration in liver cancer cells. Hepatology. 2009; 50:1130–1139.
- Rabenhorst U., Beinoraviciute-Kellner R., Brezniceanu M.-L., Joos S., Devens F., Lichter P., Rieker R.J., Trojan J., Chung H.-J., Levens D.L. et al. . Overexpression of the far upstream element binding protein 1 in hepatocellular carcinoma is required for tumor growth. Hepatology. 2009; 50:1121–1129.
- Guo L., Zaysteva O., Nie Z., Mitchell N.C., Amanda Lee J.E., Ware T., Parsons L., Luwor R., Poortinga G., Hannan R.D. et al. . Defining the essential function of FBP/KSRP proteins: Drosophila Psi interacts with the mediator complex to modulate MYC transcription and tissue growth. Nucleic Acids Res. 2016; 44:7646–7658.
- Huang P.-N., Lin J.-Y., Locker N., Kung Y.-A., Hung C.-T., Lin J.-Y., Huang H.-I., Li M.-L., Shih S.-R.. Far upstream element binding protein 1 binds the internal ribosomal entry site of enterovirus 71 and enhances viral translation and viral growth. Nucleic Acids Res. 2011; 39:9633–9648.
- Irwin N., Baekelandt V., Goritchenko L., Benowitz L.I.. Identification of two proteins that bind to a pyrimidine-rich sequence in the 3′-untranslated region of GAP-43 mRNA. Nucleic Acids Res. 1997; 25:1281–1288.
- Lin J.-Y., Li M.-L., Shih S.-R.. Far upstream element binding protein 2 interacts with enterovirus 71 internal ribosomal entry site and negatively regulates viral translation. Nucleic Acids Res. 2009; 37:47–59.
- Miro J., Laaref A.M., Rofidal V., Lagrafeuille R., Hem S., Thorel D., Mechin D., Mamchaoui K., Mouly V., Claustres M. et al. . FUBP1: a new protagonist in splicing regulation of the DMD gene. Nucleic Acids Res. 2015; 43:2378–2389.
- Bettegowda C., Agrawal N., Jiao Y., Sausen M., Wood L.D., Hruban R.H., Rodriguez F.J., Cahill D.P., McLendon R., Riggins G. et al. . Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science. 2011; 333:1453–1455.
- Singer S., Malz M., Herpel E., Warth A., Bissinger M., Keith M., Muley T., Meister M., Hoffmann H., Penzel R. et al. . Coordinated expression of stathmin family members by far upstream sequence Element-Binding Protein-1 increases motility in Non–Small cell lung cancer. Cancer Res. 2009; 69:2234–2243.
- Weber A., Kristiansen I., Johannsen M., Oelrich B., Scholmann K., Gunia S., May M., Meyer H.-A., Behnke S., Moch H. et al. . The FUSE binding proteins FBP1 and FBP3 are potential c-myc regulators in renal, but not in prostate and bladder cancer. BMC Cancer. 2008; 8:369.
- Yang L., Zhu J., Zhang J., Bao B., Guan C., Yang X., Liu Y., Huang Y., Ni R., Ji L.. Far upstream element-binding protein 1 (FUBP1) is a potential c-Myc regulator in esophageal squamous cell carcinoma (ESCC) and its expression promotes ESCC progression. Tumor Biol. 2016; 37:4115–4126.
- Rabenhorst U., Thalheimer F.B., Gerlach K., Kijonka M., Böhm S., Krause D.S., Vauti F., Arnold H.-H., Schroeder T., Schnütgen F. et al. . Single-Stranded DNA-Binding transcriptional regulator FUBP1 is essential for fetal and adult hematopoietic stem cell Self-Renewal. Cell Rep. 2015; 11:1847–1855.
- Zhou W., Chung Y.-J., Parrilla Castellar E.R., Zheng Y., Chung H.-J., Bandle R., Liu J., Tessarollo L., Batchelor E., Aplan P.D. et al. . Far upstream element binding protein plays a crucial role in embryonic development, hematopoiesis, and stabilizing Myc expression levels. Am. J. Pathol. 2016; 186:701–715.
- Klener P., Fronkova E., Berkova A., Jaksa R., Lhotska H., Forsterova K., Soukup J., Kulvait V., Vargova J., Fiser K. et al. . Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years: Mantle cell lymphoma-variant Richter syndrome. Int. J. Cancer. 2016; 139:2252–2260.
- Lindqvist C.M., Lundmark A., Nordlund J., Freyhult E., Ekman D., Almlöf J.C., Raine A., Övernäs E., Abrahamsson J., Frost B.-M. et al. . Deep targeted sequencing in pediatric acute lymphoblastic leukemia unveils distinct mutational patterns between genetic subtypes and novel relapse-associated genes. Oncotarget. 2016; 7:64071–64088.
- Landau D.A., Tausch E., Taylor-Weiner A.N., Stewart C., Reiter J.G., Bahlo J., Kluth S., Bozic I., Lawrence M., Böttcher S. et al. . Mutations driving CLL and their evolution in progression and relapse. Nature. 2015; 526:525–530.
- Ashman L.K. The biology of stem cell factor and its receptor C-kit. Int. J. Biochem. Cell Biol. 1999; 31:1037–1051.
- Broudy V.C. Stem cell factor and hematopoiesis. Blood. 1997; 90:1345–1364.
- Miettinen M., Lasota J.. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl. Immunohistochem. Mol. Morphol. 2005; 13:205–220.
- Yarden Y., Kuang W.J., Yang-Feng T., Coussens L., Munemitsu S., Dull T.J., Chen E., Schlessinger J., Francke U., Ullrich A.. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J. 1987; 6:3341–3351.
- Mohammed H., D’Santos C., Serandour A.A., Ali H.R., Brown G.D., Atkins A., Rueda O.M., Holmes K.A., Theodorou V., Robinson J.L.L. et al. . Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. Cell Rep. 2013; 3:342–349.
- Debaize L., Jakobczyk H., Rio A.-G., Gandemer V., Troadec M.-B.. Optimization of proximity ligation assay (PLA) for detection of protein interactions and fusion proteins in non-adherent cells: application to pre-B lymphocytes. Mol. Cytogenet. 2017; 10:27.
- Stewart S.A., Dykxhoorn D.M., Palliser D., Mizuno H., Yu E.Y., An D.S., Sabatini D.M., Chen I.S.Y., Hahn W.C., Sharp P.A. et al. . Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA. 2003; 9:493–501.
- Arnaud M.-P., Vallée A., Robert G., Bonneau J., Leroy C., Varin-Blank N., Rio A.-G., Troadec M.-B., Galibert M.-D., Gandemer V.. CD9, a key actor in the dissemination of lymphoblastic leukemia, modulating CXCR4-mediated migration via RAC1 signaling. Blood. 2015; 126:1802–1812.
- Campeau E., Ruhl V.E., Rodier F., Smith C.L., Rahmberg B.L., Fuss J.O., Campisi J., Yaswen P., Cooper P.K., Kaufman P.D.. A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS ONE. 2009; 4:e6529.
- Sérandour A.A., Avner S., Oger F., Bizot M., Percevault F., Lucchetti-Miganeh C., Palierne G., Gheeraert C., Barloy-Hubler F., Péron C.L. et al. . Dynamic hydroxymethylation of deoxyribonucleic acid marks differentiation-associated enhancers. Nucleic Acids Res. 2012; 40:8255–8265.
- Shin H., Liu T., Manrai A.K., Liu X.S.. CEAS: cis-regulatory element annotation system. Bioinforma. Oxf. Engl. 2009; 25:2605–2606.
- McLean C.Y., Bristor D., Hiller M., Clarke S.L., Schaar B.T., Lowe C.B., Wenger A.M., Bejerano G.. GREAT improves functional interpretation of cis-regulatory regions. Nat. Biotechnol. 2010; 28:495–501.
- Nègre D., Mangeot P.E., Duisit G., Blanchard S., Vidalain P.O., Leissner P., Winter A.J., Rabourdin-Combe C., Mehtali M., Moullier P. et al. . Characterization of novel safe lentiviral vectors derived from simian immunodeficiency virus (SIVmac251) that efficiently transduce mature human dendritic cells. Gene Ther. 2000; 7:1613–1623.
- Zheng Y., Miskimins W.K.. Far upstream element binding protein 1 activates translation of p27Kip1 mRNA through its internal ribosomal entry site. Int. J. Biochem. Cell Biol. 2011; 43:1641–1648.
- Krieger E., Vriend G.. New ways to boost molecular dynamics simulations. J. Comput. Chem. 2015; 36:996–1007.
- He L., Weber A., Levens D.. Nuclear targeting determinants of the far upstream element binding protein, a c-myc transcription factor. Nucleic Acids Res. 2000; 28:4558–4565.
- Lu J., Maruyama M., Satake M., Bae S.C., Ogawa E., Kagoshima H., Shigesada K., Ito Y.. Subcellular localization of the alpha and beta subunits of the acute myeloid leukemia-linked transcription factor PEBP2/CBF. Mol. Cell. Biol. 1995; 15:1651–1661.
- Zelent A., Greaves M., Enver T.. Role of the TEL-AML1 fusion gene in the molecular pathogenesis of childhood acute lymphoblastic leukaemia. Oncogene. 2004; 23:4275–4283.
- Melchers F. Checkpoints that control B cell development. J. Clin. Invest. 2015; 125:2203–2210.
- Atanassov B.S., Dent S.Y.R.. USP22 regulates cell proliferation by deubiquitinating the transcriptional regulator FBP1. EMBO Rep. 2011; 12:924–930.
- Rabenhorst U., Beinoraviciute-Kellner R., Brezniceanu M.-L., Joos S., Devens F., Lichter P., Rieker R.J., Trojan J., Chung H.-J., Levens D.L. et al. . Overexpression of the far upstream element binding protein 1 in hepatocellular carcinoma is required for tumor growth. Hepatol. Baltim. Md. 2009; 50:1121–1129.
- Malz M., Bovet M., Samarin J., Rabenhorst U., Sticht C., Bissinger M., Roessler S., Bermejo J.L., Renner M., Calvisi D.F. et al. . Overexpression of far upstream element (FUSE) binding protein (FBP)-interacting repressor (FIR) supports growth of hepatocellular carcinoma. Hepatology. 2014; 60:1241–1250.
- Braddock D.T., Louis J.M., Baber J.L., Levens D., Clore G.M.. Structure and dynamics of KH domains from FBP bound to single-stranded DNA. Nature. 2002; 415:1051–1056.
- Levanon D., Groner Y.. Structure and regulated expression of mammalian RUNX genes. Oncogene. 2004; 23:4211–4219.
- Sandelin A., Alkema W., Engström P., Wasserman W.W., Lenhard B.. JASPAR: an open-access database for eukaryotic transcription factor binding profiles. Nucleic Acids Res. 2004; 32:D91–D94.
- Matheny C.J., Speck M.E., Cushing P.R., Zhou Y., Corpora T., Regan M., Newman M., Roudaia L., Speck C.L., Gu T.-L. et al. . Disease mutations in RUNX1 and RUNX2 create nonfunctional, dominant-negative, or hypomorphic alleles. EMBO J. 2007; 26:1163–1175.
- Zhang L., Li Z., Yan J., Pradhan P., Corpora T., Cheney M.D., Bravo J., Warren A.J., Bushweller J.H., Speck N.A.. Mutagenesis of the Runt domain defines two energetic hot spots for heterodimerization with the core binding factor beta subunit. J. Biol. Chem. 2003; 278:33097–33104.
- Benjamin L.R., Chung H.-J., Sanford S., Kouzine F., Liu J., Levens D.. Hierarchical mechanisms build the DNA-binding specificity of FUSE binding protein. Proc. Natl. Acad. Sci. U.S.A. 2008; 105:18296–18301.
- Siomi H., Matunis M.J., Michael W.M., Dreyfuss G.. The pre-mRNA binding K protein contains a novel evolutionarily conserved motif. Nucleic Acids Res. 1993; 21:1193–1198.
- Sully G., Dean J.L.E., Wait R., Rawlinson L., Santalucia T., Saklatvala J., Clark A.R.. Structural and functional dissection of a conserved destabilizing element of cyclo-oxygenase-2 mRNA: evidence against the involvement of AUF-1 [AU-rich element/poly(U)-binding/degradation factor-1], AUF-2, tristetraprolin, HuR (Hu antigen R) or FBP1 (far-upstream-sequence-element-binding protein 1). Biochem. J. 2004; 377:629–639.
- Zhou X., Edmonson M.N., Wilkinson M.R., Patel A., Wu G., Liu Y., Li Y., Zhang Z., Rusch M.C., Parker M. et al. . Exploring genomic alteration in pediatric cancer using ProteinPaint. Nat. Genet. 2016; 48:4–6.
- Lennartsson J., Jelacic T., Linnekin D., Shivakrupa R.. Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells. 2005; 23:16–43.
- Yee N.S., Hsiau C.W., Serve H., Vosseller K., Besmer P.. Mechanism of down-regulation of c-kit receptor. Roles of receptor tyrosine kinase, phosphatidylinositol 3′-kinase, and protein kinase C. J. Biol. Chem. 1994; 269:31991–31998.
- He L., Liu J., Collins I., Sanford S., O’Connell B., Benham C.J., Levens D.. Loss of FBP function arrests cellular proliferation and extinguishes c-myc expression. EMBO J. 2000; 19:1034–1044.
- Cammenga J., Horn S., Bergholz U., Sommer G., Besmer P., Fiedler W., Stocking C.. Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate. Blood. 2005; 106:3958–3961.
- Tian Y., Wang G., Hu Q., Xiao X., Chen S.. AML1/ETO trans-activates c-KIT expression through the long range interaction between promoter and intronic enhancer. J. Cell. Biochem. 2017; 119:3706–3715.
- Liu J., He L., Collins I., Ge H., Libutti D., Li J., Egly J.-M., Levens D.. The FBP interacting repressor targets TFIIH to inhibit activated transcription. Mol. Cell. 2000; 5:331–341.
- Liu J., Chung H.-J., Vogt M., Jin Y., Malide D., He L., Dundr M., Levens D.. JTV1 co-activates FBP to induce USP29 transcription and stabilize p53 in response to oxidative stress. EMBO J. 2011; 30:846–858.
- Sykora K.W., Tomeczkowski J., Reiter A.. C-Kit receptors in childhood malignant lymphoblastic cells. Leuk. Lymphoma. 1997; 25:201–216.
- Andersson A., Olofsson T., Lindgren D., Nilsson B., Ritz C., Edén P., Lassen C., Råde J., Fontes M., Mörse H. et al. . Molecular signatures in childhood acute leukemia and their correlations to expression patterns in normal hematopoietic subpopulations. Proc. Natl. Acad. Sci. U.S.A. 2005; 102:19069–19074.
- Ikeda H., Kanakura Y., Tamaki T., Kuriu A., Kitayama H., Ishikawa J., Kanayama Y., Yonezawa T., Tarui S., Griffin J.D.. Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. Blood. 1991; 78:2962–2968.
- Weidemann R.R., Behrendt R., Schoedel K.B., Müller W., Roers A., Gerbaulet A.. Constitutive Kit activity triggers B-cell acute lymphoblastic leukemia-like disease in mice. Exp. Hematol. 2017; 45:45–55.
- Eppert K., Takenaka K., Lechman E.R., Waldron L., Nilsson B., van Galen P., Metzeler K.H., Poeppl A., Ling V., Beyene J. et al. . Stem cell gene expression programs influence clinical outcome in human leukemia. Nat. Med. 2011; 17:1086–1093.
- Gandemer V., Rio A.G., de Tayrac M., Sibut V., Mottier S., Ly Sunnaram B., Henry C., Monnier A., Berthou C., Le Gall E. et al. . Five distinct biological processes and 14 differentially expressed genes characterize TEL/AML1-positive leukemia. BMC Genomics. 2007; 8:385.
- Jiao X., Sherman B.T., Huang D.W., Stephens R., Baseler M.W., Lane H.C., Lempicki R.A.. DAVID-WS: a stateful web service to facilitate gene/protein list analysis. Bioinformatics. 2012; 28:1805–1806.
- Nicol J.W., Helt G.A., Blanchard S.G., Raja A., Loraine A.E.. The integrated genome Browser: free software for distribution and exploration of genome-scale datasets. Bioinforma. Oxf. Engl. 2009; 25:2730–2731.
- Chenna R., Sugawara H., Koike T., Lopez R., Gibson T.J., Higgins D.G., Thompson J.D.. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res. 2003; 31:3497–3500.
- Efremov R.G., Chugunov A.O., Pyrkov T.V., Priestle J.P., Arseniev A.S., Jacoby E.. Molecular lipophilicity in protein modeling and drug design. Curr. Med. Chem. 2007; 14:393–415.
Source: PubMed